The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• United Therapeutics →

  biotech company based in Silver Spring, Maryland, United States

  • United Therapeutics filed Form 13F with the Securities and Exchange Commission.Mon 11:42
  • Trump's tariff plan caused markets to tank, affecting company Flo.Sun 01:29
• Leerink partners →

  U.S. investment bank

  • Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
  • A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Related events

• United Therapeutics used Citibank for accelerated share repurchases while its products are pending review for market approval by the FDA.Sep 11
• GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Aug 4